https://www.selleckchem.com/pr....oducts/itacitinib-in
ially explained by increased falls, and to a lesser extent by shorter reproductive lifespan, in T1D.A novel cost-effectiveness model framework was developed to incorporate the elevated fracture risk associated with a recent fracture and to allow sequential osteoporosis therapies to be evaluated. Treating patients with severe osteoporosis after a recent fracture with a bone-forming agent followed by antiresorptive therapy can be cost-effective compared with antiresorptive therapy alone. Incorporating these novel technical at
Aimer
Commentaire
Partagez
